Date: 2011-03-15
Type of information:
phase: 3
Announcement: enrollment of the first patient
Company: AstraZeneca (UK)
Product: NKTR-118 (oral peripherally-acting opioid antagonist)This once-daily oral tablet combines Nektar\'s advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid antagonist drug, naloxone.
Action mechanism:
Disease: opioid-induced constipation
Therapeutic area: Digestive diseases
Country:
Trial
details: AstraZeneca has announced enrolment of the first patient in the Phase III clinical programme for NKTR-118 being investigated for the treatment of opioid-induced constipation. The Phase III clinical programme is designed to investigate the safety and efficacy of NKTR-118 as a medicine to relieve opioid induced constipation, a common side effect of prescription opioids when used for chronic pain management.
The Phase III clinical program will consist of two 12-week, randomized, placebo-controlled efficacy studies (with approximately 630 randomized patients each) and an open-label, randomized, long-term safety study with a “usual care” comparator arm. The 12-week efficacy studies will compare response rate among placebo and two different doses of NKTR-118 with primary endpoint at 4 weeks. There is a three month safety extension following one of the two 12-week studies. The long-term safety study will include patients from the 12-week treatment in the efficacy studies, as well as new patients not previously enrolled. All patients will be randomly assigned to open-label treatment of either NKTR-118 or physician’s choice (usual care) of laxative regimen. Safety assessments will also be collected throughout the trials.
Latest news: NKTR-118 is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics. The first regulatory filings based on the programme are planned for 2013.
